Accepting applications until August 1
Accepting applications until August 1
Dechuang Jiao, Jiujun Zhu, Dandan Wang, et al. Breast. 2026 Mar 23:87:104777
Accurate estimates of the global burden of young breast cancer (YBC) are lacking. In 2021, YBC accounted for substantial global disease burden, with 81,856 new cases, 687,819 prevalent cases, 18,597 deaths, and 1,178,721 DALYs. Fr... Read More
Yibei Li, Danqi Huang, Jingyi Liu, et al. J Natl Cancer Cent. 2026 Feb 11;6(2):149-158
Early-onset cancer is a significant public health threat in females, yet comprehensive data on its global burden and temporal trends remain limited. This study analyzed the incidence, mortality, and disability-adjusted life years... Read More
Silvia Mignozzi, Claudia Santucci, Gianfranco Alicandro, et al. Cancer Causes Control. 2026 Apr 3;37(5):79
An increasing cancer incidence has been observed among recent generations over the last decade. However, apart from colorectal cancer, these increases were not associated with rises in mortality. We extracted death counts for indi... Read More
Zachary J Ward, Fabio Ynoe Moraes, Andrew M Scott, et al. Lancet Oncol. 2026 May;27(5):560-568
Cancer survival has improved in many countries in recent decades, but large disparities remain globally. Understanding the effects of workforce shortages, stage at diagnosis, and broader health system barriers on poor survival is... Read More
Yingying Li, Wenfu Song, Ping Gao, et al. BMC Cancer. 2025 Feb 24;25(1):330
Female breast cancer, cervical cancer, uterine cancer, and ovarian cancer (FBCUO) pose a significant threat to global public health. Incidence, age-standardized incidence rate (ASIR), deaths, age-standardized mortality rate (ASMR)... Read More
Wenhui Ren, Xiangyu Guo, Zheng Liu, et al. Cancer. 2025;e35712. 1-11 wileyonlinelibrary.com/journal/cncr
Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. The year‐ and age‐specific estimates of the incidence, mortality, and disability‐adjusted life‐years (DALYs) associated with... Read More
GBD 2023 Cancer Collaborators. Lancet. 2025 Oct 11;406(10512):1565-1586
In 2023, excluding non-melanoma skin cancers, there were 18·5 million incident cases of cancer and 10·4 million deaths, contributing to 271 million DALYs globally. Of these, 57·9% of incident cases and 65·8% of cancer deaths occur... Read More
GBD 2023 Breast Cancer Collaborators. Lancet Oncol. 2026 Mar;27(3):302-326
Breast cancer is a leading cause of mortality and morbidity among females worldwide. In 2023, there were an estimated 2.30 million breast cancer incident cases, 764 000 deaths, and 24.1 million DALYs among females globally. In the... Read More
Chunling Hu, Steven N Hart, Rohan Gnanaolivu et al. N Engl J Med. 2021 Feb 4;384(5):440-451
In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case... Read More
Vivek Subbiah. Nature Communications. (2025) 16:4972
Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting moleculardrivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world... Read More
Sapna P Patel, Megan Othus, Yuanbin Chen et al. N Engl J Med. 2023 Mar 2;388(9):813-823
In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adju... Read More
Christian U Blank, Minke W Lucas, Richard A Scolyer et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708
In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab... Read More